Effectiveness and Cost-effectiveness of Digital Psychological Intervention (EmoEase) in Chinese COPD Patients

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age35+
SponsorPeking Union Medical College

About this trial

Background Mental health issues are common and often overlooked in COPD patients. Digital psychological interventions might help, but their effectiveness in Chinese COPD patients hasn't been studied. This study aims to develop and evaluate EmoEase, a digital psychological intervention, for its effectiveness and cost-effectiveness in improving mental wellbeing in Chinese COPD patients.

Methods This multicenter, two-arm, randomized controlled trial (RCT) will enroll at least 420 COPD patients over 35 years old. Participants will receive either usual care (control group) or usual care plus EmoEase (intervention group). Assessments will occur at baseline (T0), 4 weeks (T1), 8 weeks (T2), and 16 weeks (T3). Participants will complete questionnaires and undergo physical measurements. The primary outcome will be mental wellbeing measured by the Warwick Edinburgh Mental Wellbeing Scale (WEMWBS). Secondary outcomes will assess mental and physical health, COPD symptoms, health risk behaviors, socioeconomic factors, and healthcare use and costs. Analyses will use an intention-to-treat approach.

Discussion This is the first RCT to evaluate EmoEase for COPD patients. If effective and cost-effective, EmoEase could be scaled up to provide mental health support to COPD patients in China.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age 35 years or older;

Post-bronchodilator FEV1/FVC ≤70% or confirmed COPD patients;

Literate and able to type;

Have a smartphone;

Disqualifiers

Patients with a physician diagnosis of asthma or asthma-COPD overlap syndrome;

Patients hospitalized for COPD within the previous one year;

Having severe cognitive dysfunction and being unable to communicate;

Severely ill with less than 12-month life expectancy.

Trial design

Design model

Parallel

Treatments tested in this trial

  • EmoEase

    Behavioral

    The online intervention"EmoEase" integrates two distinct trainings for anxiety and depression. Each training includes approximately twenty 10-minute sessions, and each are centered around different themes. These two trainings will be delivered through a WeChat Mini Program.

Treatment groups

1,200 Participants
are divided into 2 treatment groups
Group A: usual care + EmoEase groupExperimental treatment 1 intervention
Group B: usual careNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

the Warwick Edinburgh Mental Wellbeing Scale (WEMWBS)

Patients' mental wellbeing at baseline, and each follow-up is assessed using the Warwick Edinburgh Mental Wellbeing Scale (WEMWBS). The Chinese version of the scale shows good psychometric properties WEMWBS is a self-report measure comprising 14 short statements focusing on positive wellbeing. Each statement is rated on a 5-point Likert scale, resulting in scores ranging from 14 to 70 (a higher score indicates better mental wellbeing).

Time frame
at baseline (T0), 4 weeks (T1), 8 weeks (T2), and 16 weeks (T3) after baseline

Secondary outcomes

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: